Savolitinib - AstraZeneca/HUTCHMED
Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; VoressaLatest Information Update: 02 Aug 2024
At a glance
- Originator Hutchison MediPharma
- Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
- Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase III Renal cell carcinoma
- Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Prostate cancer
- No development reported CNS cancer; Solid tumours
Most Recent Events
- 31 Jul 2024 Preregistration for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO)
- 31 Jul 2024 HUTCHMED announces intention to submit NDA to US FDA for Non-small cell lung cancer in the US, at year end 2024
- 24 Jun 2024 AstraZeneca completes a phase I trial (In volunteers) in Sweden (PO) (NCT06348355, EudraCT2023-508334-34-00)